Clinical Study on Induction of Remission Using Bortezomib (Vel), Cyclophosphamide (C), and Dexamethasone (D) in Patients Until 60 Years of Age With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy: (VelCD; Deutsche Studiengruppe Multiples Myelom [DSMM] XIa)

Trial Profile

Clinical Study on Induction of Remission Using Bortezomib (Vel), Cyclophosphamide (C), and Dexamethasone (D) in Patients Until 60 Years of Age With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy: (VelCD; Deutsche Studiengruppe Multiples Myelom [DSMM] XIa)

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Dec 2014

At a glance

  • Drugs Bortezomib (Primary) ; Cyclophosphamide; Dexamethasone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 17 Apr 2013 Planned number of patients changed from 400 to 401 as reported by German Clinical Trials Register.
    • 06 Jun 2012 New source identified and integrated (German Clinical Trials Register; DRKS00003762).
    • 04 Aug 2009 Actual end date (May 2009) and actual number of patients (399) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top